FDA shifts IND safety reporting over to FAERS in finalized guidance
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsCompliancePharmaceuticalsPharmacovigilanceRegulatory writing/documentationUnited States